A5046477718- Transplantation: Methods and Outcomes
- Renal Transplantation Outcomes and Treatments
- Mechanical Circulatory Support Devices
- Viral Infections and Immunology Research
- Organ Transplantation Techniques and Outcomes
- Cardiac Structural Anomalies and Repair
- Organ and Tissue Transplantation Research
- Polyomavirus and related diseases
- Cytomegalovirus and herpesvirus research
- Hepatitis C virus research
- Cardiac Valve Diseases and Treatments
- Cardiac pacing and defibrillation studies
- Heart Failure Treatment and Management
- Cardiovascular Issues in Pregnancy
- Pneumocystis jirovecii pneumonia detection and treatment
- Heparin-Induced Thrombocytopenia and Thrombosis
- Cardiac Arrest and Resuscitation
- Liver Disease and Transplantation
- Cardiac Ischemia and Reperfusion
- Cardiovascular Function and Risk Factors
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Coronary Interventions and Diagnostics
- Organ Donation and Transplantation
- Blood groups and transfusion
- Neurological Complications and Syndromes
Cedars-Sinai Smidt Heart Institute
2016-2025
Cedars-Sinai Medical Center
2016-2025
New York University
2024
University Hospital Münster
2022
University Medical Center Hamburg-Eppendorf
2022
Osaka University
2020
University of Minnesota
2002-2020
Alpha Star (United States)
2020
Royal College of Surgeons in Ireland - Bahrain
2020
Sinai Health System
2012-2020
Hypercholesterolemia is common after cardiac transplantation and may contribute to the development of coronary vasculopathy. Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has been shown be effective safe in lowering cholesterol levels transplantation. Cell-culture studies using inhibitors HMG-CoA have suggested an immunosuppressive effect.
Everolimus, a novel proliferation inhibitor and immunosuppressive agent, may suppress cardiac-allograft vasculopathy. We conducted randomized, double-blind, clinical trial comparing everolimus with azathioprine in recipients of first heart transplant.A total 634 patients were randomly assigned to receive 1.5 mg per day (209 patients), 3.0 (211 or 1.0 kilogram body weight (214 combination cyclosporine, corticosteroids, statins. The primary efficacy end point was composite death, graft loss...
Background. After heart transplantation, 1-year and 5-year survival rates are 79% 63%, respectively, with rejection, infection, allograft coronary artery disease accounting for the majority of deaths. Mycophenolate mofetil (MMF), an inhibitor de novo pathway purine biosynthesis, decreases rejection in animals human renal transplantation. Methods. In a double-blind, active-controlled trial, 28 centers randomized 650 patients undergoing their first transplant to receive MMF (3000 mg/day) or...
Rejection diagnosis by endomyocardial biopsy (EMB) is invasive, expensive and variable. We investigated gene expression profiling of peripheral blood mononuclear cells (PBMC) to discriminate ISHLT grade 0 rejection (quiescence) from moderate/severe (ISHLT > or = 3A). Patients were followed prospectively with sampling at post-transplant visits. Biopsies graded criteria locally three independent pathologists blinded clinical data. Known alloimmune pathways leukocyte microarrays identified 252...
The process of humoral rejection is multifaceted and has different manifestations in the various types organ transplants. Because this emerging as a leading cause graft loss, conference was held April 2003 to comprehensively address issues regarding rejection. Though may result from factors, discussion focused on paradigm caused by antibodies, typically against donor HLA antigens, term 'antibody-mediated rejection' (AMR). Conference deliberations were separated into four workgroups:...
The most advantageous combination of immunosuppressive agents for cardiac transplant recipients has not yet been established. Between November 2001 and June 2003, 343 de novo were randomized to receive steroids either tacrolimus (TAC) + sirolimus (SRL), TAC mycophenolate mofetil (MMF) or cyclosporine (CYA) MMF. Antilymphocyte induction therapy was allowed up 5 days. primary endpoint ≥3A rejection hemodynamic compromise requiring treatment showed no significant difference at 6 months (TAC/MMF...
The availability of direct-acting antiviral agents for the treatment hepatitis C virus (HCV) infection has resulted in a profound shift approach to management this infection. These changes have affected practice solid organ transplantation by altering framework which patients with end-stage disease are managed and receive transplants. high level safety efficacy these medications chronic HCV provides opportunity explore their use setting transplanting organs from HCV-viremic into...
The presence of preexisting (memory) or de novo donor-specific HLA antibodies (DSAs) is a known barrier to successful long-term organ transplantation. Yet, despite the fact that laboratory tools and our understanding histocompatibility have advanced significantly in recent years, criteria define DSA assign level risk for given vary markedly between centers. A collaborative effort American Society Histocompatibility Immunogenetics Transplantation provided logistical support generating...
In an open-label, 24-month trial, 721 <i>de novo</i> heart transplant recipients were randomized to everolimus 1.5 mg or 3.0 with reduced-dose cyclosporine, mycophenolate mofetil (MMF) 3 g/day standard-dose cyclosporine (plus corticosteroids ± induction). Primary efficacy endpoint was the 12-month composite incidence of biopsy-proven acute rejection, rejection associated hemodynamic compromise, graft loss/retransplant, death loss follow-up. Everolimus noninferior MMF for this at month 12...
A consensus conference on frailty in kidney, liver, heart, and lung transplantation sponsored by the American Society of Transplantation (AST) endorsed Nephrology (ASN), Transplant Surgeons (ASTS), Canadian (CST) took place February 11, 2018 Phoenix, Arizona. Input from transplant community through scheduled calls enabled wide discussion current concepts frailty, exploration best practices for risk assessment candidates management after transplant, development ideas future research....
Standardized donor-derived cell-free DNA (dd-cfDNA) testing has been introduced into clinical use to monitor kidney transplant recipients for rejection. This report describes the performance of this dd-cfDNA assay detect allograft rejection in samples from heart (HT) undergoing surveillance monitoring across United States. Venous blood was longitudinally sampled 740 HT 26 centers and a single-center cohort 33 patients at high risk antibody-mediated (AMR). Plasma quantified by using targeted...